Clinical Trial Update: Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR) [Phase 3]

View source ↗

Summary

Phase III trial evaluating the glimepiride plus metformin hydrochloride extended-release combination (Amaryl M SR) for type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride + Metformin Hydrochloride SR (Amaryl M SR)

Snippet

Sponsor: Handok Inc. | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED